RADX Radiopharm Theranostics | $4.77
+3.0% | 7/21/2025 | Kemp Dolliver | Upgrade | Strong-Buy | $18.00 | View details for Brookline Capital Management rating of Radiopharm Theranostics (NASDAQ:RADX) on 7/21/2025 |
LSTA Lisata Therapeutics | $2.66
+0.4% | 7/15/2025 | Kemp Dolliver | Boost Price Target | Buy -> Buy | $20.00 -> $32.00 | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 7/15/2025 |
CADL Candel Therapeutics | $7.00
+0.6% | 7/9/2025 | K. Dolliver | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Candel Therapeutics (NASDAQ:CADL) on 7/9/2025 |
HURA TuHURA Biosciences | $2.84
-3.7% | 6/23/2025 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of TuHURA Biosciences (NASDAQ:HURA) on 6/23/2025 |
BIVI BioVie | $7.55
-8.4% | 3/18/2025 | T. Bussian | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of BioVie (NASDAQ:BIVI) on 3/18/2025 |
CRVO CervoMed | $8.05
-2.4% | 3/11/2025 | T. Bussian | Upgrade | Hold -> Strong-Buy | | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 3/11/2025 |
CATX Perspective Therapeutics | $4.15
-4.6% | 3/10/2025 | K. Dolliver | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Perspective Therapeutics (NYSE:CATX) on 3/10/2025 |
IMAB I-Mab | $2.12
+0.5% | 2/27/2025 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 2/27/2025 |
MRKR MARKER THERAPEUTICS | $1.50
-6.3% | 2/10/2025 | L. Cann | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of MARKER THERAPEUTICS (NASDAQ:MRKR) on 2/10/2025 |
CGTX Cognition Therapeutics | $0.86
+7.0% | 1/27/2025 | T. Bussian | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Cognition Therapeutics (NASDAQ:CGTX) on 1/27/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
MDCX Medicus Pharma | $3.02
-1.0% | 12/23/2024 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Medicus Pharma (NASDAQ:MDCX) on 12/23/2024 |
EXEL Exelixis | $44.79
-1.3% | 12/23/2024 | L. Cann | Initiated Coverage | Buy | | View details for Brookline Capital Management rating of Exelixis (NASDAQ:EXEL) on 12/23/2024 |
QNCX Quince Therapeutics | $1.86
| 12/18/2024 | K. Raja | Initiated Coverage | Buy | $9.00 | View details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024 |
CRVO CervoMed | $8.05
-2.4% | 12/10/2024 | T. Bussian | Downgrade | Strong-Buy -> Hold | | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024 |
YMAB Y-mAbs Therapeutics | $4.84
+0.6% | 12/4/2024 | K. Dolliver | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024 |
YMAB Y-mAbs Therapeutics | $4.84
+0.6% | 12/5/2024 | - | Initiated Coverage | Buy | $17.00 | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024 |
HYPD Hyperion DeFi | $8.17
-12.3% | 11/15/2024 | K. Dolliver | Reiterated Rating | Buy -> Hold | | View details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 11/15/2024 |
COCH Envoy Medical | $1.63
+1.9% | 10/14/2024 | T. Bussian | Initiated Coverage | Buy | $9.00 | View details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024 |
VRCA Verrica Pharmaceuticals | $0.70
-0.7% | 10/2/2024 | K. Dolliver | Reiterated Rating | Buy -> Hold | | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024 |
OSTX OS Therapies | $1.73
-5.5% | 8/22/2024 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024 |
IBIO iBio | $0.74
-2.8% | 7/22/2024 | K. Dolliver | Initiated Coverage | Buy | $3.60 | View details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024 |
UNCY Unicycive Therapeutics | $4.85
+5.2% | 7/9/2024 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024 |
CRVO CervoMed | $8.05
-2.4% | 7/8/2024 | T. Bussian | Initiated Coverage | Buy | $63.00 | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024 |
SABS SAB Biotherapeutics | $2.60
+4.4% | 6/7/2024 | - | Initiated Coverage | Buy | $8.00 | View details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024 |
FBRX Forte Biosciences | $10.75
+1.0% | 5/30/2024 | - | Initiated Coverage | Buy | $4.00 | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024 |
DARE Dare Bioscience | $2.63
-1.1% | 5/15/2024 | K. Dolliver | Upgrade | Hold -> Buy | $36.00 | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 5/15/2024 |
DARE Dare Bioscience | $2.63
-1.1% | 4/17/2024 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $1.07
+7.3% | 4/5/2024 | T. Bussian | Reiterated Rating | Buy | $10.00 | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
ATBPF Antibe Therapeutics | $0.22
| 3/4/2024 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $2.86
+7.5% | 2/28/2024 | T. Bussian | Downgrade | Buy -> Hold | $9.00 | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
OTLK Oncobiologics | $2.00
-3.8% | 1/25/2024 | K. Dolliver | Upgrade | Hold -> Buy | $31.40 | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 1/25/2024 |
CYCC Cyclacel Pharmaceuticals | $17.15
+22.5% | 12/19/2023 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 12/19/2023 |
LNTH Lantheus | $70.93
-3.2% | 11/30/2023 | - | Initiated Coverage | Buy | $100.00 | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $2.86
+7.5% | 11/10/2023 | T. Bussian | Reiterated Rating | Buy | $35.00 | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $3.47
-3.6% | 10/30/2023 | K. Dolliver | Upgrade | Hold -> Buy | | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
HYPD Hyperion DeFi | $8.17
-12.3% | 10/17/2023 | - | Initiated Coverage | Buy | $640.00 | View details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 10/17/2023 |
EDSA Edesa Biotech | $2.40
+0.8% | 10/12/2023 | - | Reiterated Rating | Buy -> Buy | $57.00 | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
OTLK Oncobiologics | $2.00
-3.8% | 8/30/2023 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 8/30/2023 |
ATBPF Antibe Therapeutics | $0.22
| 8/14/2023 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
DARE Dare Bioscience | $2.63
-1.1% | 2/14/2023 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 2/14/2023 |
The Trump Dump is starting; Get out of stocks now? (Ad) The first 365 days of the Trump presidency…
Will be the best time to get rich in American history. If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a |
ECOR electroCore | $7.47
+1.9% | 1/12/2023 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
VXRT Vaxart | $0.41
-2.9% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022 |
OTLK Oncobiologics | $2.00
-3.8% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $46.82
-0.1% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
LSTA Lisata Therapeutics | $2.66
+0.4% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
EDSA Edesa Biotech | $2.40
+0.8% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
CYCC Cyclacel Pharmaceuticals | $17.15
+22.5% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 10/3/2022 |
ARCT Arcturus Therapeutics | $14.95
-3.2% | 8/10/2022 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22
| 6/30/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $0.60
+2.7% | 5/18/2022 | Kumaraguru Raja | Boost Price Target | Buy -> Buy | $29.00 -> $31.00 | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $0.70
-0.7% | 3/10/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $12.78
-10.3% | 3/7/2022 | L. Cann | Upgrade | Hold -> Buy | $91.00 | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $66.06
-3.1% | 2/14/2022 | Leah Rush | Reiterated Rating | Buy | $143.00 | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $12.78
-10.3% | 2/14/2022 | Leah Rush | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $2.37
-4.4% | 2/14/2022 | L. Cann | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
BCDA BioCardia | $2.31
-3.8% | 2/3/2022 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022 |
ICCM IceCure Medical | $0.99
+1.5% | 2/1/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
DARE Dare Bioscience | $2.63
-1.1% | 1/19/2022 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 1/19/2022 |
KYMR Kymera Therapeutics | $45.85
-1.2% | 10/13/2021 | Leah Rush Cann | Reiterated Rating | Buy | $80.00 | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $10.75
+1.0% | 9/3/2021 | K. Raja | Reiterated Rating | Hold | | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $0.60
+2.7% | 8/27/2021 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $0.74
+0.5% | 8/24/2021 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $2.29
-5.4% | 6/25/2021 | Leah Rush Cann | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATBPF Antibe Therapeutics | $0.22
| 6/3/2021 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $46.82
-0.1% | 5/25/2021 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $3.70
-0.8% | 5/7/2021 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
MRNA Moderna | $34.01
-1.9% | 2/26/2021 | - | Boost Price Target | Buy | $180.00 -> $205.00 | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
VERU Veru | $0.60
+2.7% | 12/14/2020 | K. Raja | Boost Price Target | | $13.00 -> $17.00 | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
ECOR electroCore | $7.47
+1.9% | 10/23/2020 | S. Yanchus | Initiated Coverage | Buy | $75.00 | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
FBRX Forte Biosciences | $10.75
+1.0% | 8/28/2020 | K. Raja | Initiated Coverage | Buy | $90.00 | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
KURA Kura Oncology | $6.47
+0.5% | 8/16/2020 | L. Cann | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $0.60
+2.7% | 8/14/2020 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $14.95
-3.2% | 8/11/2020 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
MRNA Moderna | $34.01
-1.9% | 7/13/2020 | L. Cann | Reiterated Rating | Buy | $95.00 | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.75
-2.7% | 6/3/2020 | - | Initiated Coverage | Buy | $3.50 | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
CYCC Cyclacel Pharmaceuticals | $17.15
+22.5% | 5/19/2020 | K. Raja | Initiated Coverage | Buy | $79,200.00 | View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 5/19/2020 |
OTLK Oncobiologics | $2.00
-3.8% | 5/5/2020 | K. Raja | Initiated Coverage | Buy | | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 5/5/2020 |
DARE Dare Bioscience | $2.63
-1.1% | 4/28/2020 | S. Yanchus | Initiated Coverage | Buy | $90.00 | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $2.40
+0.8% | 3/30/2020 | K. Raja | Initiated Coverage | Buy | $70.00 | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $11.28
-2.6% | 3/11/2020 | S. Yanchus | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $2.48
+3.3% | 3/13/2020 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $11.28
-2.6% | 3/12/2020 | - | Initiated Coverage | Buy | $15.00 | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $46.82
-0.1% | 2/19/2020 | K. Raja | Initiated Coverage | Buy | $210.00 | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $3.70
-0.8% | 2/4/2020 | S. Yanchus | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
BCDA BioCardia | $2.31
-3.8% | 11/26/2019 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
BCDA BioCardia | $2.31
-3.8% | 11/26/2019 | - | Initiated Coverage | Buy | $330.00 | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
MDNA Medicenna Therapeutics | C$0.83
-2.4% | 11/19/2019 | - | Reiterated Rating | Buy | C$4.00 | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
SCYX SCYNEXIS | $0.74
+0.5% | 8/19/2019 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT Vaxart | $0.41
-2.9% | 8/15/2019 | K. Raja | Initiated Coverage | Buy | $6.00 | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019 |
VERU Veru | $0.60
+2.7% | 7/29/2019 | K. Raja | Initiated Coverage | Buy | $12.00 | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
The Trump Dump is starting; Get out of stocks now? (Ad) The first 365 days of the Trump presidency…
Will be the best time to get rich in American history. If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a |
CLRB Cellectar Biosciences | $5.35
-4.3% | 7/29/2019 | K. Raja | Initiated Coverage | Buy | $1,800.00 -> $1,800.00 | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019 |
ARCT Arcturus Therapeutics | $14.95
-3.2% | 7/24/2019 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
SCYX SCYNEXIS | $0.74
+0.5% | 1/4/2019 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
CLRB Cellectar Biosciences | $5.35
-4.3% | 11/20/2018 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018 |
ARCT Arcturus Therapeutics | $14.95
-3.2% | 9/27/2018 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $44.72
-1.8% | 7/27/2018 | K. Raja | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $44.72
-1.8% | 5/1/2018 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |
